Moreover, empagliflozin improved endothelium-dependent relaxations in streptozotocin-induced diabetic rats [44], reduced atherosclerotic plaque formation in ApoE−/− mice by improving the inflammatory response and insulin resistance [45], and improved endothelial function in an experimental model of metabolic syndrome the ZSF1 rat [46]. Here, APOE is linked to metabolic syndrome.